These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27838867)

  • 41. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
    Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
    Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
    Barau C; Delaugerre C; Braun J; de Castro N; Furlan V; Charreau I; Gérard L; Lascoux-Combe C; Molina JM; Taburet AM
    Antimicrob Agents Chemother; 2010 Feb; 54(2):937-9. PubMed ID: 19995925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.
    Mata-Marín JA; Smeke AE; Rodriguez MR; Chávez-García M; Banda-Lara MI; Rios AM; Nuñez-Rodríguez N; Domínguez-Hermosillo JC; Sánchez AC; Juarez-Kasusky I; Herrera JE; Ramírez JL; Gaytán-Martínez J
    Drugs R D; 2017 Mar; 17(1):225-231. PubMed ID: 28124232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system.
    Horberg MA; Oakes AH; Hurley LB; Towner WJ; Chao CR; Silverberg MJ; Chantra JQ; Ellis CG; Quesenberry CP
    HIV Clin Trials; 2018 Oct; 19(5):177-187. PubMed ID: 30370835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.
    Rudek MA; Moore PC; Mitsuyasu RT; Dezube BJ; Aboulafia D; Gerecitano J; Sullivan R; Cianfrocca ME; Henry DH; Ratner L; Haigentz M; Dowlati A; Little RF; Ivy SP; Deeken JF
    Cancer; 2014 Apr; 120(8):1194-202. PubMed ID: 24474568
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
    Casado JL; Bañón S; Rodriguez MA; Moreno A; Moreno S
    Antiviral Res; 2015 Jan; 113():103-6. PubMed ID: 25460844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.
    Casado JL; Bañón S
    Expert Rev Clin Pharmacol; 2015; 8(6):709-18. PubMed ID: 26517111
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Raltegravir use prospectively assessed in a major HIV outpatient clinic in Italy: sample population, virological-immunological activity, and tolerability profile.
    Manfredi R; Calza L; Marinacci G; Cascavilla A; Colangeli V; Salvadori C; Martelli G; Appolloni L; Puggioli C; Viale P
    Infez Med; 2014 Dec; 22(4):288-95. PubMed ID: 25551844
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium.
    Patten G; Puthanakit T; McGowan CC; Wools-Kaloustian K; Hazra R; Pinto JA; Machado D; Succi R; Sohn AH; Rabie H; Musick B; Davies MA;
    J Int AIDS Soc; 2020 Jul; 23(7):e25580. PubMed ID: 32722897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study.
    Calza L; Danese I; Colangeli V; Vandi G; Manfredi R; Girometti N; Borderi M; Appolloni L; Puggioli C; Viale P
    AIDS Res Hum Retroviruses; 2014 Dec; 30(12):1162-9. PubMed ID: 25369244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
    Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
    AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients.
    Huerta García G; Mata-Marín JA; Domínguez-Hermosillo JC; Chavez-García M; Banda-Lara MI; Nuñez-Rodríguez N; Cruz-Herrera JE; Sandoval-Ramírez JL; Villagómez-Ruiz A; Manjarrez-Tellez B; Gaytan-Martínez JE
    J Infect Dev Ctries; 2016 Jun; 10(6):605-11. PubMed ID: 27367009
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age Study.
    Pavone P; Giustini N; Fimiani C; Paoletti F; Falciano M; Salotti A; Di Sora F; Al Moghazi S; Mezzaroma I; Vullo V; d'Ettorre G
    Curr HIV Res; 2017 Nov; 15(5):355-360. PubMed ID: 28969567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.